Because the histone deacetylase inhibitor (HDACI) vorinostat showed excellent outcomes for treating advanced CTCL, HDACIs may reduce the metastasis of CTCL by targeting miR-150 and/ or CCR6. This evidence concerns the gene CCR6 and primary cutaneous T-cell non-Hodgkin lymphoma.